Country Trust Bank Has $40.24 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Country Trust Bank lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 204,771 shares of the medical research company’s stock after selling 8,450 shares during the quarter. Country Trust Bank owned approximately 0.11% of IQVIA worth $40,240,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in IQV. Simplify Asset Management Inc. grew its holdings in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Nordea Investment Management AB grew its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Smith Group Asset Management LLC acquired a new stake in IQVIA in the 4th quarter valued at about $1,616,000. Fifth Third Bancorp raised its stake in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after acquiring an additional 1,521 shares during the last quarter. Finally, Versor Investments LP bought a new stake in shares of IQVIA during the third quarter valued at approximately $1,328,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Up 1.7 %

Shares of NYSE:IQV opened at $201.42 on Friday. The firm has a market cap of $36.56 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 2.12 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company’s fifty day simple moving average is $200.42 and its 200 day simple moving average is $220.65.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Leerink Partners restated an “outperform” rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft lowered their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.